GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » H. Lundbeck AS (OCSE:HLUN A) » Definitions » Moat Score

H. Lundbeck AS (OCSE:HLUN A) Moat Score : 6/10 (As of Jul. 23, 2025)


View and export this data going back to 2022. Start your Free Trial

What is H. Lundbeck AS Moat Score?

H. Lundbeck AS has the Moat Score of 6, which implies that the company might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

H. Lundbeck AS has Narrow Moat: Lundbeck has a strong narrow moat due to its valuable pharmaceutical patents and consistent R&D capabilities. Its brand strength in the CNS disorder market supports customer loyalty, but regulatory challenges and competition limit a wider moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes H. Lundbeck AS might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Competitive Comparison of H. Lundbeck AS's Moat Score

For the Drug Manufacturers - Specialty & Generic subindustry, H. Lundbeck AS's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

H. Lundbeck AS's Moat Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, H. Lundbeck AS's Moat Score distribution charts can be found below:

* The bar in red indicates where H. Lundbeck AS's Moat Score falls into.


;
;

H. Lundbeck AS  (OCSE:HLUN A) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

H. Lundbeck AS Moat Score Related Terms

Thank you for viewing the detailed overview of H. Lundbeck AS's Moat Score provided by GuruFocus.com. Please click on the following links to see related term pages.

H. Lundbeck AS Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » H. Lundbeck AS (OCSE:HLUN A) » Definitions » Moat Score
Comparable Companies
OCSE:STENO ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD XSWX:SDZ HKSE:03692 NSE:DIVISLAB XTAE:TEVA SHSE:688506 TSE:4507 BOM:500087 SZSE:000538 NSE:TORNTPHARM UTHR BOM:500124 NBIX BOM:532321
Traded in Other Exchanges
HLBBF:USA HLUBF:USA HLUNBc:UK 0ABR:UK 0ND5:UK HLUN B:Denmark LDBB:Germany LUNB:Austria LUNA:Austria
Address
Ottiliavej 9, Valby, DNK, 2500
Website
https://www.lundbeck.com
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.

H. Lundbeck AS Headlines

No Headlines